A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients With PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients With PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
This is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the efficacy and safety of rilvegostomig compared to pembrolizumab as a 1L treatment for patients with mNSCLC whose tumors express PD-L1.
Inclusion Criteria:
Exclusion Criteria:
information.center@astrazeneca.com1-877-240-9479
CABA, 1425, Argentina
Libramont-Chevigny, 6800, Belgium
Roeselaere, 8800, Belgium
Conception, 4070196, Chile
Haerbin, 150081, China
San José Capital, 1000, Costa Rica
Torrette Di Ancona, 60126, Italy
Iwakuni-shi, 740-8510, Japan
Izumi-shi, 594-0073, Japan
Kurume-shi, 830-0011, Japan
Nankoku-shi, 783-8505, Japan
Shinagawa-ku, 142-8666, Japan
Takarazuka-shi, 665-0827, Japan
Toon-Shi, 791-0295, Japan
Toyoake-shi, 470-1192, Japan
Toyonaka-shi, 560-8552, Japan